GPX1 Gene Links Frailty and Hypertension With Two Natural Compounds as Targets

Frailty and hypertension are among the most prevalent and intertwined conditions affecting older adults, yet shared molecular targets that could address both simultaneously remain poorly defined. This study sought to bridge that gap using a multi-layered genomic and computational approach.

Investigators performed a two-sample Mendelian randomization analysis — a method that uses genetic variants as proxies for drug targets to infer causal relationships — across 2,532 druggable genes. GPX1, encoding the antioxidant enzyme glutathione peroxidase 1, emerged as a standout candidate. Higher GPX1 expression in whole blood was causally associated with increased hypertension risk and higher frailty index scores, findings independently validated using RNA expression profiling datasets.

Mediation analyses revealed that the amino acid glycine and the metabolites carnitine and ergothioneine partially explain how GPX1 influences these outcomes. Single-cell RNA sequencing confirmed these metabolic mediators operate at the cellular level, particularly in mononuclear phagocytes — immune cells where GPX1 expression correlated with upregulated inflammatory and immune activation pathways, suggesting a mechanistic link between oxidative stress regulation, metabolism, and aging-related decline.

Molecular docking analysis identified two naturally occurring compounds — biochanin A (an isoflavone found in red clover) and epigallocatechin gallate or EGCG (a polyphenol abundant in green tea) — as high-affinity binders to GPX1, flagging them as candidate therapeutic agents worth further investigation.

Caveats apply: the study is primarily genetic and computational, and causal findings from Mendelian randomization require validation in clinical trials. The paradoxical positive association between an antioxidant enzyme and adverse outcomes also warrants mechanistic clarification before therapeutic development proceeds.